Quarter
Charts

CorMedix Inc.

CRMD

CIK 0001410098 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$129M
↑+312.1% +$97Mvs FY2024 (Q4)
Operating Income
$59M
↑+108.5% +$31Mvs FY2024 (Q4)
Net Income
$14M
↓-50.5% -$14Mvs FY2024 (Q4)
Gross Profit
$116M
↑+286.1% +$86Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
69/100
  • Profitability
    100ROIC 61.3% (10% = solid, 20%+ = moat)
  • Liquidity
    80Current Ratio 2.11 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    35Asset Turnover 0.66x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +312.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 46.0% · trend +1012.4pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project CRMD's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$37011.68
Total enterprise IV
$2.97B
Diluted shares
0.00B
Terminal PV
$2.15B (72% of total)
Year-5 FCF
$254M
YearProjected FCFDiscounted PV
+1$187M$170M
+2$202M$167M
+3$218M$164M
+4$235M$161M
+5$254M$158M
Terminal$3.47B$2.15B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$2M
investment in PP&E
Stock-based comp (TTM)
$14M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$826M
everything owned
Total liabilities
$421M
everything owed
Stockholders' equity
$405M
shareholder claim

Recent performance · 63 quarters

Revenue↑+312.1% +$97M
$129M
Net Income
$14M
Free Cash Flow↑+914796.5% +$93M
$93M
Operating Margin
46.0%

Drill down

CRMD Sankey

See CorMedix Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

CRMD Charts

63 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

CRMD Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics